Literature DB >> 22885643

The correlation between human papillomavirus positivity and abnormal cervical cytology result differs by age among perimenopausal women.

Anne F Rositch1, Michelle I Silver, Anne Burke, Raphael Viscidi, Kathryn Chang, Cindy M P Duke, Wen Shen, Patti E Gravitt.   

Abstract

OBJECTIVES: We explored the age-stratified correlates and correlations between high-risk human papillomavirus (HR-HPV) infection and cervical abnormalities in perimenopausal women.
MATERIALS AND METHODS: Human papillomavirus testing and Pap smear screening were performed at baseline on 841 routinely screened women age 35 to 60 years in the HPV in perimenopause cohort. Demographic, behavioral, and medical information was collected through telephone-administered questionnaires. Descriptive analyses were used to examine the correlation between HR-HPV infection and cervical abnormalities by age. Logistic regression was used to determine correlates of HPV and abnormalities in women younger and older than 45 years.
RESULTS: The prevalence of HPV, HR-HPV, and cervical abnormalities decreased significantly with increasing age, as did the correlation between HR-HPV and cervical abnormalities. The prevalence of HR-HPV was 50% among younger women with abnormalities but this decreased steadily to 20% HR-HPV detection among 50- to 54-year-old women, and no abnormalities were detected in 55- to 60-year-old women. Different correlates of HR-HPV infection and abnormalities were observed in women 45 years or older, a pattern not seen in younger women.
CONCLUSIONS: Although the relative proportion of low-grade and high-grade abnormalities did not change with age, we saw a loss of concordance between HR-HPV detection and cytological abnormalities with increasing age. Current guidelines for cervical cancer screening group together all women age 30 years and older. Our data raise important questions about the interpretation of HPV and Pap test results in this age group and suggest that ongoing surveillance of HPV and cytology in cervical cancer screening programs consider a third age stratification among older women.

Entities:  

Mesh:

Year:  2013        PMID: 22885643      PMCID: PMC3499667          DOI: 10.1097/LGT.0b013e3182503402

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  22 in total

1.  HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology.

Authors:  Guglielmo Ronco; Jack Cuzick; Nereo Segnan; Silvia Brezzi; Francesca Carozzi; Stefania Folicaldi; Paolo Dalla Palma; Annarosa Del Mistro; Anna Gillio-Tos; Pamela Giubilato; Carlo Naldoni; Enzo Polla; Anna Iossa; Manuel Zorzi; Massimo Confortini; Paolo Giorgi-Rossi
Journal:  Eur J Cancer       Date:  2007-01-12       Impact factor: 9.162

Review 2.  Age-specific prevalence of infection with human papillomavirus in females: a global review.

Authors:  Jennifer S Smith; Amy Melendy; Rashida K Rana; Jeanne M Pimenta
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

3.  Age-related changes of the cervix influence human papillomavirus type distribution.

Authors:  Philip E Castle; Jose Jeronimo; Mark Schiffman; Rolando Herrero; Ana C Rodríguez; M Concepción Bratti; Allan Hildesheim; Sholom Wacholder; L Rodney Long; Leif Neve; Ruth Pfeiffer; Robert D Burk
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

4.  Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.

Authors:  Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Concepción Bratti; Mark E Sherman; Diane Solomon; Diego Guillén; Mario Alfaro; Jorge Morales; Martha Hutchinson; Hormuzd Katki; Li Cheung; Sholom Wacholder; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2010-02-15       Impact factor: 13.506

5.  Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology.

Authors:  Delphine Maucort-Boulch; Martyn Plummer; Philip E Castle; Franklin Demuth; Mahboobeh Safaeian; Cosette M Wheeler; Mark Schiffman
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

6.  Burden of cervical cancer in the United States, 1998-2003.

Authors:  Meg Watson; Mona Saraiya; Vicki Benard; Steven S Coughlin; Lisa Flowers; Vilma Cokkinides; Molly Schwenn; Youjie Huang; Anna Giuliano
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

Review 7.  2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests.

Authors:  Thomas C Wright; L Stewart Massad; Charles J Dunton; Mark Spitzer; Edward J Wilkinson; Diane Solomon
Journal:  Am J Obstet Gynecol       Date:  2007-10       Impact factor: 8.661

8.  A comparison of cervical and vaginal human papillomavirus.

Authors:  Philip E Castle; Ana C Rodriguez; Carolina Porras; Rolando Herrero; Mark Schiffman; Paula Gonzalez; Allan Hildesheim; Robert D Burk
Journal:  Sex Transm Dis       Date:  2007-11       Impact factor: 2.830

9.  Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions.

Authors:  S Brismar-Wendel; M Froberg; A Hjerpe; S Andersson; B Johansson
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

10.  Syndromic management and STI control in urban Peru.

Authors:  Jesse L Clark; Andres G Lescano; Kelika A Konda; Segundo R Leon; Franca R Jones; Jeffrey D Klausner; Thomas J Coates; Carlos F Caceres
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more
  11 in total

1.  Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.

Authors:  Julia C Gage; William C Hunt; Mark Schiffman; Hormuzd A Katki; Li C Cheung; Jack Cuzick; Orrin Myers; Philip E Castle; Cosette M Wheeler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-10-30       Impact factor: 4.254

2.  Participation in Cervical Screening by Self-collection, Pap, or a Choice of Either in Brazil.

Authors:  Philip E Castle; Vânia R S Silva; Marcia E L Consolaro; Nádia Kienen; Lorna Bittencourt; Sandra M Pelloso; Edward E Partridge; Amanda Pierz; Camila B Dartibale; Nelson S Uchimura; Isabel C Scarinci
Journal:  Cancer Prev Res (Phila)       Date:  2019-01-16

3.  Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection.

Authors:  Julia C Gage; Hormuzd A Katki; Mark Schiffman; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Philip E Castle; Walter K Kinney
Journal:  Int J Cancer       Date:  2014-09-02       Impact factor: 7.396

4.  Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women.

Authors:  Anne F Rositch; Anne E Burke; Raphael P Viscidi; Michelle I Silver; Kathryn Chang; Patti E Gravitt
Journal:  Cancer Res       Date:  2012-09-27       Impact factor: 12.701

5.  A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States.

Authors:  Patti E Gravitt; Anne F Rositch; Michelle I Silver; Morgan A Marks; Kathryn Chang; Anne E Burke; Raphael P Viscidi
Journal:  J Infect Dis       Date:  2012-12-12       Impact factor: 5.226

6.  Evidence of disrupted high-risk human papillomavirus DNA in morphologically normal cervices of older women.

Authors:  Sarah M Leonard; Merlin Pereira; Sally Roberts; Kate Cuschieri; Gerard Nuovo; Ramanand Athavale; Lawrence Young; Raji Ganesan; Ciarán B Woodman
Journal:  Sci Rep       Date:  2016-02-15       Impact factor: 4.379

7.  Evidence and impact of human papillomavirus latency.

Authors:  Patti E Gravitt
Journal:  Open Virol J       Date:  2012-12-28

8.  Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy.

Authors:  Rebecca M Brotman; Michelle D Shardell; Pawel Gajer; Doug Fadrosh; Kathryn Chang; Michelle I Silver; Raphael P Viscidi; Anne E Burke; Jacques Ravel; Patti E Gravitt
Journal:  Menopause       Date:  2014-05       Impact factor: 3.310

9.  Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study).

Authors:  Grazyna Stanczuk; Gwendoline Baxter; Heather Currie; James Lawrence; Kate Cuschieri; Allan Wilson; Marc Arbyn
Journal:  BMJ Open       Date:  2016-04-25       Impact factor: 2.692

10.  Evaluation of PCR-Reverse Dot Blot Human Papillomavirus Genotyping Test in Predicting Residual/Recurrent CIN 2+ in Posttreatment Patients in China.

Authors:  Qiaoyu Zhang; Binhua Dong; Lihua Chen; Tingting Lin; Yao Tong; Wenyu Lin; Haifeng Lin; Yuqin Gao; Fen Lin; Pengming Sun
Journal:  Cancer Manag Res       Date:  2020-04-01       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.